| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/09/2004 | US20040176462 NPY Y5 antagonist |
| 09/09/2004 | US20040176461 Sulfonyl-amino or carbonyl-amino derivatives; osteoporosis bone disorders; therapeutic drug or kits including anti-resorptive agents, anabolic agents; |
| 09/09/2004 | US20040176457 Novel NIDDM regimen |
| 09/09/2004 | US20040176456 Method of treatment for sexual dysfunction |
| 09/09/2004 | US20040176455 Deprenyl compounds for treatment of glaucoma |
| 09/09/2004 | US20040176454 with water-soluble amino acids; treatment of gangrene |
| 09/09/2004 | US20040176453 Method of treating time-dependent changes in human subjects |
| 09/09/2004 | US20040176452 Enriched for t10,c12 and c9,t11 isomers; greater nutritional and therapeutic use |
| 09/09/2004 | US20040176451 Pparg agonistic medicinal compositions |
| 09/09/2004 | US20040176450 Formoterol tartrate polymorph |
| 09/09/2004 | US20040176449 Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use. |
| 09/09/2004 | US20040176448 Use of carnitine and/or one or more acyl-carnitines for producing cosmetic or dermatological preparations, which increase ceramide biosynthesis |
| 09/09/2004 | US20040176447 water-soluble amino acid; infection is selected from the group consisting of. dysentery, gangrene, hepatitis, herpes, pneumonia, syphilis, and typhoid fever |
| 09/09/2004 | US20040176446 Substituted amino dicarboxylic acid derivatives |
| 09/09/2004 | US20040176444 Phenylalkyloxy-phenyl derivatives |
| 09/09/2004 | US20040176443 Capsaicin receptor ligands |
| 09/09/2004 | US20040176442 Potassium taurate bicarbonate and ascorbate |
| 09/09/2004 | US20040176439 coadministration of agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F) |
| 09/09/2004 | US20040176438 Novel mono- and di-fluorinated beozothiepine copmunds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
| 09/09/2004 | US20040176437 Novel compounds for treatment of cardiac arrhythmia, synthesis, and methods of use |
| 09/09/2004 | US20040176436 Tryptophanyl-esters and their N-acyl derivatives for preventing and treating diseases caused or aggravated by oxidation processes |
| 09/09/2004 | US20040176435 example compound: (3S)-3-(1-Benzothien-7-yloxy)-N-methyl-3-phenyl-1-propanamine oxalate; depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation and pain |
| 09/09/2004 | US20040176434 Pyrazoloanthrone derivatives as Jun N-terminal kinase inhibitors; diabetes; obesity |
| 09/09/2004 | US20040176433 treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis |
| 09/09/2004 | US20040176431 Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use |
| 09/09/2004 | US20040176428 treatment of Type 2 diabetes mellitus, obesity and lipid disorders; coadministration with HMG CoA reductase inhibitors |
| 09/09/2004 | US20040176427 Alpha type human peroxisome proliferator activated receptor agonists; such as 2-methyl-2-(3-methyl-4-(((4-phenoxymethyl-2-(4-trifluoromethylphenyl) -thiazol-5-yl-carbonyl)-amino)-methyl)phenoxy)propionic acid |
| 09/09/2004 | US20040176425 Cycloalkyl containing anilide ligands for the thyroid receptor |
| 09/09/2004 | US20040176423 HMG-CoA reductase inhibitor with a prostaglandin agonist; treating cartilage defects or disorders or promoting wound healing |
| 09/09/2004 | US20040176422 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 09/09/2004 | US20040176421 such as 1,4-Bis-{N-[3-(3-aminomethylphenylproplonyl)-2-methoxycarbonylpyrrolidin-4-yl]aminocarbonyloxy}-2-butyne dihydrochloride; for treatment of asthma, allergic conjunctivitis, allergic rhinitis, psoriasis, and ulcerative colitis |
| 09/09/2004 | US20040176420 Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 09/09/2004 | US20040176419 particularly chronic obstructive pulmonary disease (COPD), asthma or a related pulmonary disease such as chronic bronchitis or allergic rhinitis |
| 09/09/2004 | US20040176417 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands |
| 09/09/2004 | US20040176414 principle metabolite of cisapride; has both 5-HT3 antagonistic and 5-HT4 agonistic; devoid of central nervous system effects; separating racemic mixture by liquid chromatography over a chiral stationary phase |
| 09/09/2004 | US20040176412 Process for the preparation of threo-methylphenidate hydrochloride |
| 09/09/2004 | US20040176411 especially useful for treating asthma and/or rhinitis; example compound N-[[[2-[4-(3,4-dichlorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-4-methyl-benzenesulfonamide |
| 09/09/2004 | US20040176408 alpha 1 antagonist such as phenoxybenzamine and a phentolamine; characterized by its ability to contract a pupil of a human patient's eye so that the pupil is twice the size or less in dim light as compared to its size in bright light |
| 09/09/2004 | US20040176406 Pyrido [2,1-a] isoquinoline derivatives |
| 09/09/2004 | US20040176404 Methods and reagents for treating or preventing atherosclerosis and diseases associated therewith |
| 09/09/2004 | US20040176403 Methods for treating multidrug resistance |
| 09/09/2004 | US20040176402 Controlled-release compositions containing opioid agonist and antagonist |
| 09/09/2004 | US20040176400 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| 09/09/2004 | US20040176397 (Oxo-Pyrazolo[1,5a]pyrimidin-2-yl)Alkyl-Carboxamides |
| 09/09/2004 | US20040176396 anti-protoazoal; poultry feed; therapy for cytokine mediated disease i.e. osteoarthritis, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption diseases, reperfusion injury, graft v. host rejection |
| 09/09/2004 | US20040176395 Anti-cancer medicaments |
| 09/09/2004 | US20040176394 Administering heterocyclic esters such as 5-(2,4-Dimethyl-phenyl)-3-(8-hydroxy-quinolin-2-ylamino)-5-methyl-dihydro-furan-2-one for prophylaxis of headaches, sepsis, neurodegenerative diseases, or as analgesics, antiischemic or antidiabetic agents |
| 09/09/2004 | US20040176393 2-(4'-bromobiphenyl-4-sulfonylamino)-3-methylbutyric acid with atorvastatin |
| 09/09/2004 | US20040176391 prophylaxis against a pulmonary fungal infection; delivering from 5 mg to 10 mg of amphotericin B when aerosolized |
| 09/09/2004 | US20040176389 Piperazine oxime dervatives having nk-1 receptor antagonistic activity |
| 09/09/2004 | US20040176388 example compound: cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indole; treatment of CNS and other disorders |
| 09/09/2004 | US20040176387 Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies |
| 09/09/2004 | US20040176386 Compounds |
| 09/09/2004 | US20040176385 treating cancer by inhibiting phosphotidylinositol 3-kinase; in combination with other known agents to modulate cellular proliferation |
| 09/09/2004 | US20040176384 inhibit Tissue factor expression and vascular permeability factor expression in cancer cells and in vascular endothelial cells in the tumor microenvironment; low toxicity to normal vascular endothelial cells |
| 09/09/2004 | US20040176382 treatment of inflammation, proliferative diseases, and certain cardiovascular disorders as well as Alzheimer's disease; |
| 09/09/2004 | US20040176381 Methotrexate compliance packaging |
| 09/09/2004 | US20040176379 agonist effect from one or more of a somatostatin subtype receptor; diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X; inhibiting the proliferation of helicobacter pylori |
| 09/09/2004 | US20040176375 Benzene acetamide compounds useful as serine protease inhibitors |
| 09/09/2004 | US20040176374 Arylsulfonamides as antiviral agents |
| 09/09/2004 | US20040176373 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and an agent used in the treatment of the cardiac conditions associated with diabetes mellitus |
| 09/09/2004 | US20040176372 Pin1-modulating compounds and methods of use thereof |
| 09/09/2004 | US20040176371 1,6-Dihydropyrazolo[4,3-d]pyridine-7-thione derivatives; phosphodiesterase inhibitors; side effect reduction; chlorosulfonation; thionation |
| 09/09/2004 | US20040176366 Method of preventing or treating atherosclerosis or restenosis |
| 09/09/2004 | US20040176364 Aryl substituted thiazinidinones and the use thereof |
| 09/09/2004 | US20040176363 N-Acylpiperazine derivatives; cardiovascular disorders; anticoagulants |
| 09/09/2004 | US20040176362 Matrix metalloproteinase inhibitors, treatment of tumor necrosis factor mediated diseases; autoimmune and neurodegenerative disorders; anticarcinogenic and antiinflammatory agents |
| 09/09/2004 | US20040176361 2H-Isoquinolin-1-one derivatives as poly/ADP-ribose/ polymerase inhibitors |
| 09/09/2004 | US20040176360 Administering taurolidine, taurultam, or a biologically active derivative to mammal to directly contact tumor cell at dosage sufficient to induce cell death by apoptosis; side effect reduction |
| 09/09/2004 | US20040176359 Intranasal Benzodiazepine compositions |
| 09/09/2004 | US20040176358 Compositions and methods relating to novel compounds and targets thereof |
| 09/09/2004 | US20040176357 Stable, amorphous , lyophilized, parenteral injections comprising olanzapine, solubilizer and stabilizer; bipolar, psychological and neurodegenerative disorders; anxiolytic agents;schizophrenia |
| 09/09/2004 | US20040176354 Treatment of congestive heart failure |
| 09/09/2004 | US20040176353 Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| 09/09/2004 | US20040176349 Antibacterial composition |
| 09/09/2004 | US20040176347 Synergistic mixture of astrocyte function-improving agent and tissue plasminogen activator thrombolytic agent |
| 09/09/2004 | US20040176346 Cytostatic lanthanum compounds |
| 09/09/2004 | US20040176345 Administering a quenching photosensitizer molecule for side effect reduction to retinal pigmented epithelium; age related macular degeneration |
| 09/09/2004 | US20040176344 Method to treat patients with amyotrophic lateral sclerosis and the like |
| 09/09/2004 | US20040176343 Platinum amine glycine complex derivatives; antiproliferative and antitumor agents; side effect reduction; reversibly active; on and off |
| 09/09/2004 | US20040176342 Fluticasone lotion having improved vasoconstrictor activity |
| 09/09/2004 | US20040176341 Injectable sustained release delivery devices |
| 09/09/2004 | US20040176339 Antineoplastic combinations |
| 09/09/2004 | US20040176338 Pharmaceutical compositions based on anticholinergics and corticosteroids |
| 09/09/2004 | US20040176337 Benzoquinolizine-2-carboxylic acid-containing compositions |
| 09/09/2004 | US20040176336 Hormonal regimen comprising norgestimate and an estrogen |
| 09/09/2004 | US20040176335 Novel cocrystallization |
| 09/09/2004 | US20040176334 7-and 9- carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds |
| 09/09/2004 | US20040176330 Tyrosine phosphatase (PTP-1B) inhibitors; anticarcinogenic agents; neurodegenerative disorders |
| 09/09/2004 | US20040176329 Treating Alzheimer*s, Parkinson*s, and Binswanger*s disease; antiischemic agents, dementia; nervous system, brain and neurodegenerative disorders |
| 09/09/2004 | US20040176328 Encapsulated bioactive bisphosphonate such as alendronate including mono- or diglyceride of caproic or capric acid enhancer or surfactant comprising ethylene oxide-propylene oxide block copolymer |
| 09/09/2004 | US20040176327 Use of bisphosphonic acids for treating angiogenesis |
| 09/09/2004 | US20040176326 N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof |
| 09/09/2004 | US20040176325 P38 MAP kinase inhibitors comprising indazole derivatives; antiinflammatory and antiproliferative agents; autoimmune, bone, and neurodegenerative disorders; viricides, infections |
| 09/09/2004 | US20040176324 Derivatives of 4,7-ethanothiopyrano[3,4-c]pyrrole-1,3-(2H)-dione, 4,7-epoxy-1H-isoindole-1,3(2H)-dione, and/or 4,7-ethano-1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives; autoimmune diseases; anticarcinogenic agents |
| 09/09/2004 | US20040176323 Pharmaceutical composition comprising lysophophatidic acid |
| 09/09/2004 | US20040176321 9-Fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid derivatives; basic amino acid or cyclodextrin solubilizer; microbiocide injections |
| 09/09/2004 | US20040176320 Use of at least one glycoinhibitor substance |
| 09/09/2004 | US20040176319 Cellular uptake of bioactive agents |
| 09/09/2004 | US20040176318 Pretreating with lipophilic substituted saccharide |